Dr Wouter Zandee provides his thoughts on the symptomatic control of functioning pancreatic NET

Video Transcript

My name is Wouter Zandee, I am an Endocrinologist at the University Medical Center Groningen.

And today I will be discussing how to reduce hormone symptoms from functioning pancreatic neuroendocrine tumours (NETs).

These functioning pancreatic NETs are rare but require specific treatment to reduce the symptoms of hypersecretion to increase quality of life.

Symptom Control

Also, symptom control is required to safely perform surgery or to treat with systemic therapy.

In general, two options exist for reduction of symptoms.

First of all reduction of tumour burden can be considered in accordance with the ENETS guidelines. This can be done with surgery, either curative or with debulking surgery or PRRT with Lu177-DOTATATE, and liver directed therapies can be effective.

Specifically, for hormone secretion several options are also available which I would like to discuss in more detail.

First line therapy is generally a somatostatin analogue (SSA) because of low toxicity and proven decreases in hormone secretion.

SSAs can also decrease glucagon secretion, which increases hypoglycemia in small numbers of patients with an insulinoma. So, for patients with an insulinoma the first administration is done clinically.

If an SSA is ineffective in controlling the hormone symptoms, PRRT with Lu177-DOTATATE is especially effective for patients with functioning pNETs. It has a symptomatic response rate of 71% and increases the quality of life for these patients.

Also everolimus can decrease hypoglycemia in patients with an insulinoma.

In case series sunitinib has been prescribed to decrease diarrhoea for patients with a VIPoma. So, these drugs can also be effective for these patients.

Conclusion

In conclusion, adequate control of symptoms is essential for patients with a functioning pNET to increase quality of life.

Generally, SSAs are first line therapy but if these prove ineffective PRRT can be especially effective in these patients.

Thank you for watching on behalf of NET CONNECT.

Dr Wouter Zandee graduated from medical school in 2010 at the Leiden University with a thesis on the surgical treatment of medullary thyroid carcinoma. Thereafter he started his training to become an internist-endocrinologist. He is currently a fellow in endocrinology at the Erasmus Medical Center, Rotterdam, focusing on several types of endocrine tumors. In the neuroendocrine tumor department he is a sub-investigator of multicenter trials. Concurrently he is pursuing a PhD on neuroendocrine tumors, focusing on biomarkers, treatment of hormonal syndromes (mainly with 177Lu-DOTATATE) and quality of care.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Ipsen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Ipsen and from Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

3

of 3

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Assoc. Prof. Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
PanCAN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Ipsen USA.